Combined functional genome survey of therapeutic targets for hepatocellular carcinoma

Reiko Satow, Miki Shitashige, Yae Kanai, Fumitaka Takeshita, Hidenori Ojima, Takafumi Jigami, Kazufumi Honda, Tomoo Kosuge, Takahiro Ochiya, Setsuo Hirohashi, Tesshi Yamada

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Purpose: The outcome of patients with advanced hepatocellular carcinoma (HCC) has remained unsatisfactory. Patients with HCC suffer from chronic hepatitis or liver cirrhosis, and their reserve liver function is often limited. Experimental Design: To develop new therapeutic agents that act specifically on HCC but interfere only minimally with residual liver function, we searched for genes that were upregulated in 20 cases of HCC [namely, discovery sets 1 (n = 10) and 2 (n = 10)] in comparison with corresponding nontumorous liver and a panel representing normal organs using high-density microarrays capable of detecting all exons in the human genome. Results: Eleven transcripts whose expression was significantly increased in HCC were subjected to siRNA-based secondary screening of genes required for HCC cell proliferation as well as quantitative reverse transcription-PCR analysis [validation sets 1 (n = 20) and 2 (n = 44)] and immunohistochemistry (n = 19). We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice. Conclusions: The four genes we identified were highly expressed in HCC, and HCC cells are highly dependent on these genes for proliferation. Although many important genes must have been overlooked, the selected genes were biologically relevant. The combination of genome-wide expression and functional screening described here is a rapid and comprehensive approach that could be applied in the identification of therapeutic targets in any type of human malignancy.

Original languageEnglish
Pages (from-to)2518-2528
Number of pages11
JournalClinical Cancer Research
Volume16
Issue number9
DOIs
Publication statusPublished - 2010 May 1
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Genome
Genes
Therapeutics
Small Interfering RNA
Liver
Surveys and Questionnaires
Gene Knockdown Techniques
Human Genome
Chronic Hepatitis
Heterografts
Liver Cirrhosis
Reverse Transcription
Exons
Research Design
Immunohistochemistry
Cell Proliferation
Polymerase Chain Reaction
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. / Satow, Reiko; Shitashige, Miki; Kanai, Yae; Takeshita, Fumitaka; Ojima, Hidenori; Jigami, Takafumi; Honda, Kazufumi; Kosuge, Tomoo; Ochiya, Takahiro; Hirohashi, Setsuo; Yamada, Tesshi.

In: Clinical Cancer Research, Vol. 16, No. 9, 01.05.2010, p. 2518-2528.

Research output: Contribution to journalArticle

Satow, R, Shitashige, M, Kanai, Y, Takeshita, F, Ojima, H, Jigami, T, Honda, K, Kosuge, T, Ochiya, T, Hirohashi, S & Yamada, T 2010, 'Combined functional genome survey of therapeutic targets for hepatocellular carcinoma', Clinical Cancer Research, vol. 16, no. 9, pp. 2518-2528. https://doi.org/10.1158/1078-0432.CCR-09-2214
Satow, Reiko ; Shitashige, Miki ; Kanai, Yae ; Takeshita, Fumitaka ; Ojima, Hidenori ; Jigami, Takafumi ; Honda, Kazufumi ; Kosuge, Tomoo ; Ochiya, Takahiro ; Hirohashi, Setsuo ; Yamada, Tesshi. / Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 9. pp. 2518-2528.
@article{f2091e9b329148f3bf13d302ea2bc413,
title = "Combined functional genome survey of therapeutic targets for hepatocellular carcinoma",
abstract = "Purpose: The outcome of patients with advanced hepatocellular carcinoma (HCC) has remained unsatisfactory. Patients with HCC suffer from chronic hepatitis or liver cirrhosis, and their reserve liver function is often limited. Experimental Design: To develop new therapeutic agents that act specifically on HCC but interfere only minimally with residual liver function, we searched for genes that were upregulated in 20 cases of HCC [namely, discovery sets 1 (n = 10) and 2 (n = 10)] in comparison with corresponding nontumorous liver and a panel representing normal organs using high-density microarrays capable of detecting all exons in the human genome. Results: Eleven transcripts whose expression was significantly increased in HCC were subjected to siRNA-based secondary screening of genes required for HCC cell proliferation as well as quantitative reverse transcription-PCR analysis [validation sets 1 (n = 20) and 2 (n = 44)] and immunohistochemistry (n = 19). We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice. Conclusions: The four genes we identified were highly expressed in HCC, and HCC cells are highly dependent on these genes for proliferation. Although many important genes must have been overlooked, the selected genes were biologically relevant. The combination of genome-wide expression and functional screening described here is a rapid and comprehensive approach that could be applied in the identification of therapeutic targets in any type of human malignancy.",
author = "Reiko Satow and Miki Shitashige and Yae Kanai and Fumitaka Takeshita and Hidenori Ojima and Takafumi Jigami and Kazufumi Honda and Tomoo Kosuge and Takahiro Ochiya and Setsuo Hirohashi and Tesshi Yamada",
year = "2010",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-09-2214",
language = "English",
volume = "16",
pages = "2518--2528",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Combined functional genome survey of therapeutic targets for hepatocellular carcinoma

AU - Satow, Reiko

AU - Shitashige, Miki

AU - Kanai, Yae

AU - Takeshita, Fumitaka

AU - Ojima, Hidenori

AU - Jigami, Takafumi

AU - Honda, Kazufumi

AU - Kosuge, Tomoo

AU - Ochiya, Takahiro

AU - Hirohashi, Setsuo

AU - Yamada, Tesshi

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose: The outcome of patients with advanced hepatocellular carcinoma (HCC) has remained unsatisfactory. Patients with HCC suffer from chronic hepatitis or liver cirrhosis, and their reserve liver function is often limited. Experimental Design: To develop new therapeutic agents that act specifically on HCC but interfere only minimally with residual liver function, we searched for genes that were upregulated in 20 cases of HCC [namely, discovery sets 1 (n = 10) and 2 (n = 10)] in comparison with corresponding nontumorous liver and a panel representing normal organs using high-density microarrays capable of detecting all exons in the human genome. Results: Eleven transcripts whose expression was significantly increased in HCC were subjected to siRNA-based secondary screening of genes required for HCC cell proliferation as well as quantitative reverse transcription-PCR analysis [validation sets 1 (n = 20) and 2 (n = 44)] and immunohistochemistry (n = 19). We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice. Conclusions: The four genes we identified were highly expressed in HCC, and HCC cells are highly dependent on these genes for proliferation. Although many important genes must have been overlooked, the selected genes were biologically relevant. The combination of genome-wide expression and functional screening described here is a rapid and comprehensive approach that could be applied in the identification of therapeutic targets in any type of human malignancy.

AB - Purpose: The outcome of patients with advanced hepatocellular carcinoma (HCC) has remained unsatisfactory. Patients with HCC suffer from chronic hepatitis or liver cirrhosis, and their reserve liver function is often limited. Experimental Design: To develop new therapeutic agents that act specifically on HCC but interfere only minimally with residual liver function, we searched for genes that were upregulated in 20 cases of HCC [namely, discovery sets 1 (n = 10) and 2 (n = 10)] in comparison with corresponding nontumorous liver and a panel representing normal organs using high-density microarrays capable of detecting all exons in the human genome. Results: Eleven transcripts whose expression was significantly increased in HCC were subjected to siRNA-based secondary screening of genes required for HCC cell proliferation as well as quantitative reverse transcription-PCR analysis [validation sets 1 (n = 20) and 2 (n = 44)] and immunohistochemistry (n = 19). We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice. Conclusions: The four genes we identified were highly expressed in HCC, and HCC cells are highly dependent on these genes for proliferation. Although many important genes must have been overlooked, the selected genes were biologically relevant. The combination of genome-wide expression and functional screening described here is a rapid and comprehensive approach that could be applied in the identification of therapeutic targets in any type of human malignancy.

UR - http://www.scopus.com/inward/record.url?scp=77951721529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951721529&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-2214

DO - 10.1158/1078-0432.CCR-09-2214

M3 - Article

C2 - 20388846

AN - SCOPUS:77951721529

VL - 16

SP - 2518

EP - 2528

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -